Osiris Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Osiris Therapeutics's estimated annual revenue is currently $300M per year.
- Osiris Therapeutics's estimated revenue per employee is $1,685,393
- Osiris Therapeutics's total funding is $95M.
Employee Data
- Osiris Therapeutics has 178 Employees.
- Osiris Therapeutics grew their employee count by -1% last year.
Osiris Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.9M | 6 | 20% | N/A | N/A |
#2 | $2.9M | 38 | -31% | $17.5M | N/A |
#3 | $2.9M | 38 | -33% | $10.5M | N/A |
#4 | $19.8M | 128 | 0% | $69.4M | N/A |
#5 | $11.3M | 73 | -10% | N/A | N/A |
#6 | $1.4M | 9 | 0% | N/A | N/A |
#7 | $1.9M | 12 | 9% | N/A | N/A |
#8 | $7.4M | 48 | 17% | N/A | N/A |
#9 | $1.1M | 7 | -53% | N/A | N/A |
#10 | $1.1M | 7 | 0% | N/A | N/A |
What Is Osiris Therapeutics?
Osiris Therapeutics, Inc., is a private development stage biotechnology company that develops adult mesenchymal stem cells (`MSCs") for the regeneration of bone marrow stroma, bone, cartilage and heart muscle tissues that have been damaged by injury, aging or degenerative disease. Osiris is also developing adult MSCs as a delivery platform for gene therapy.
keywords:N/A$95M
Total Funding
178
Number of Employees
$300M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Osiris Therapeutics News
Osiris Therapeutics; NuVasive; Chiesi Pharmaceuticals; Medi-post; JCR Pharmaceutical; MolMed; Pharmicell; Anterogen; Takeda (TiGenix); CBR...
Osiris Therapeutics Medipost Co. Ltd., Anterogen Co. Ltd., Pharmicell Co. Ltd., HolostemTerapieAvanzateSrl, JCR Pharmaceuticals Co.
In April 2019, Osiris Therapeutics, Inc. Announces the Closing of Acquisition by Smith & Nephew plc through the consummation of a merger of...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $43.1M | 178 | 29% | N/A |
#2 | $30.3M | 179 | -14% | N/A |
#3 | $15M | 179 | 10% | N/A |
#4 | $28.7M | 180 | 44% | N/A |
#5 | $19.9M | 181 | -18% | N/A |
Osiris Therapeutics Executives
Name | Title |
---|---|
Alla Danilkovitch | Chief Scientific Officer |